Dinutuximab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dinutuximab. Educational only — not medical advice.
Labeled uses
Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy [see Clinical Studies (14) ] .
Source: FDA labeling via NIH DailyMed (set d66bdf0d…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.